Varixio® selected for funding

Share on twitter
Twitter
Share on linkedin
LinkedIn

Our Varixio® project has been selected for funding by the EU's Horizon 2020 research and innovation programme.

The project is based on the fact that approximately 25% of adults have varicose veins, with prevalence increasing to over 80% if spider veins are also considered. The rising geriatric population is further accelerating these figures, as one in two people over the age of 50 are affected by varicose veins.

In recent years, due to the possibility of infection and other adverse effects during invasive surgeries, traditional surgical treatment (surgical ligation and stripping) has given way to minimally invasive procedures, which also reduce hospital stays and costs.

Consequently, a growing number of doctors are adopting foam sclerotherapy, endovenous laser treatment, and radio-frequency ablation over conventional surgical practices. Within these new treatment approaches, foam sclerotherapy is the preferred approach given its favourable efficacy and safety profile coupled with simplicity and relatively low cost.

Foam sclerotherapy involves transforming a chemical sclerosing agent into foam and injecting it into the affected vein. The sclerosant foam irritates the lining of the blood vessel, causing it to collapse and stick together.

Current manual foam preparation method broadly utilised by doctors (Tessari’s method) presents substantial limitations in terms of quality, consistency, versatility, and safety. VARIXIO® Sclerotherapy Microfoam System being developed by VB Devices addresses these limitations by automating, standardising, and greatly simplifying foam preparation. VARIXIO® adds versatility and safety to this obsolete treatment method.

Having secured patent protection for the device and validated the concept at the prototype level, the company has recently obtained funding to pursue industrial, regulatory, and commercial feasibility of the VARIXIO® device.

Varixio gets funding